Neuropsychiatric Symptoms and Psychotropic Medication Use Following SARS-Cov-2 Infection Among Elderly Residents in Long-Term Care Facilities DOI Open Access

Diana Cruz-Santiago,

Xiangfei Meng, Michelle Canac‐Marquis

и другие.

Canadian Geriatrics Journal, Год журнала: 2025, Номер 28(1), С. 67 - 72

Опубликована: Март 5, 2025

SARS-CoV-2 infection can lead to persistent post-acute neuropsychiatric symptoms. Older adults with multimorbidity may be at increased risk of symptoms after COVID-19. The goals the present study were assess associations and psychotropic medication prescription among older living in long-term care facilities. Nursing home residents (n=111) participated this three-month longitudinal study. Nurse ratings conducted baseline follow-up. status extracted from a medical chart review. About 73.9% participants infected on average 480.49 (SD= 228) days before enrollment. There no significant changes during follow-up period. Participants had more agitation compared those who never infected. However, effect disappeared adjusting for age, sex, history psychiatric disorder, neurocognitive status, multimorbidity. higher number prescription. This was driven by use antidepressants antipsychotic medications. Both acute short-term associated COVID-19 contribute psychoactive polypharmacy

Язык: Английский

Psychotropic Polypharmacy in Dementia: A Retrospective Analysis for People with Neuropsychiatric Symptoms Referred to an Australian Dementia Support Service DOI Creative Commons
Mustafa Atee, Andrew Stafford, Daniel Whiting

и другие.

Drugs & Aging, Год журнала: 2025, Номер unknown

Опубликована: Янв. 21, 2025

Despite their limited benefits and serious adverse effects, psychotropics remain frequently prescribed for neuropsychiatric symptoms (NPS) of dementia. Psychotropic polypharmacy, the use two or more concomitant psychotropic medications, is therefore not recommended people with The objectives this study were to investigate prevalence polypharmacy in Australians living dementia whose caregivers sought external NPS support from Dementia Support Australia (DSA; national provider support) association demographics characteristics. A retrospective cross-sectional a subset DSA referrals at baseline (i.e., yet receive psychosocial intervention(s)) between 2016 2020 was conducted. Referrals without compared on basis demographic characteristics (e.g., sex, subtype), type agitation), severity associated caregiver distress as measured by Neuropsychiatric Inventory (NPI), using Pearson's chi-square test Welch's t-test categorical continuous data, respectively. Logistic regression models used examine relationship individual NPI domains exposure polypharmacy. total 421 (mean age 81.5 (standard deviation 8.5) years, 52.3% males, 46.8% Alzheimer's disease) analysed. Of those, over 90% (n = 383) least one psychotropic, 214 (50.8%) medication types most antipsychotics 162, 75.7%), opioids 104, 48.6%), anxiolytics 93, 43.5%), sedative/hypnotics 52, 24.3%) antidepressants 47, 22.0%). No any variable tested identified, including age, subtype severity. highly prevalent referred dementia-specific behaviour programs, but no factors its presence cohort.

Язык: Английский

Процитировано

0

Neuropsychiatric Symptoms and Psychotropic Medication Use Following SARS-Cov-2 Infection Among Elderly Residents in Long-Term Care Facilities DOI Open Access

Diana Cruz-Santiago,

Xiangfei Meng, Michelle Canac‐Marquis

и другие.

Canadian Geriatrics Journal, Год журнала: 2025, Номер 28(1), С. 67 - 72

Опубликована: Март 5, 2025

SARS-CoV-2 infection can lead to persistent post-acute neuropsychiatric symptoms. Older adults with multimorbidity may be at increased risk of symptoms after COVID-19. The goals the present study were assess associations and psychotropic medication prescription among older living in long-term care facilities. Nursing home residents (n=111) participated this three-month longitudinal study. Nurse ratings conducted baseline follow-up. status extracted from a medical chart review. About 73.9% participants infected on average 480.49 (SD= 228) days before enrollment. There no significant changes during follow-up period. Participants had more agitation compared those who never infected. However, effect disappeared adjusting for age, sex, history psychiatric disorder, neurocognitive status, multimorbidity. higher number prescription. This was driven by use antidepressants antipsychotic medications. Both acute short-term associated COVID-19 contribute psychoactive polypharmacy

Язык: Английский

Процитировано

0